Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.

Front Pharmacol · 2023 · PMC10090662 · PMID 37063275

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

5Z-7-oxozeaenol and riociguat combined treatment induced a significant trend to the normalization of glucose and 2-hydroxybutyrate concentrations.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.